{"id":1235,"date":"2026-11-02T08:57:26","date_gmt":"2026-11-02T06:57:26","guid":{"rendered":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/"},"modified":"2026-11-02T09:00:30","modified_gmt":"2026-11-02T07:00:30","slug":"withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/","title":{"rendered":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in PTEN-deficient metastatic hormone-responsive prostate cancer. Withdrawal is a strategic decision, not simply a failure.<\/strong><\/p>\n<h2>Why companies withdraw<\/h2>\n<p>An applicant may withdraw at any stage before the Committee adopts its opinion. Typical reasons include an anticipated negative outcome, a need for additional data that cannot be provided within the clock, or a change in commercial or clinical priorities. EMA publishes withdrawal information and, for new-indication variations, an assessment report is normally made available.<\/p>\n<h2>What a withdrawal does and does not do<\/h2>\n<ul><li><strong>The authorised indications are unaffected.<\/strong> The existing marketing authorisation continues unchanged.<\/li><li><strong>Resubmission remains possible.<\/strong> A new application can follow once the evidence gap has been addressed.<\/li><li><strong>The record is public.<\/strong> Clinicians, payers and competitors can read why the application stalled.<\/li><\/ul>\n<h2>Lessons for planning an extension<\/h2>\n<p>Extensions of indication are Type II variations and are scrutinised for the strength of the pivotal evidence, the relevance of the comparator and the clinical meaning of the endpoint. Early scientific advice on the proposed wording, subgroup definition and biomarker strategy is often more valuable than late-stage rescue.<\/p>\n<h2>Withdrawal versus waiting<\/h2>\n<p>Withdrawing can be better than receiving a negative opinion, because it preserves flexibility. The decision should be taken with full awareness of the timetable, the consequences for any linked national procedures and the effect on ongoing HTA work, where the indication was the basis of a reimbursement case.<\/p>\n<h2>How PQRA helps<\/h2>\n<p>PQRA advises on variation strategy, including whether to proceed to opinion, withdraw or resubmit, and coordinates the knock-on effects on labelling, national procedures and Greek reimbursement planning.<\/p>\n<p><strong><a href=\"\/el\/contact\/\">Contact PQRA to discuss your situation<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in PTEN-deficient metastatic hormone-responsive prostate cancer. Withdrawal is a strategic decision, not simply a failure. Why companies withdraw An applicant may withdraw at any stage before the Committee adopts its opinion. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1259,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA\" \/>\n<meta property=\"og:description\" content=\"The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in PTEN-deficient metastatic hormone-responsive prostate cancer. Withdrawal is a strategic decision, not simply a failure. Why companies withdraw An applicant may withdraw at any stage before the Committee adopts its opinion. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T06:57:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-02T07:00:30+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u03bb\u03b5\u03c0\u03c4\u03cc\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026\",\"datePublished\":\"2026-11-02T06:57:26+00:00\",\"dateModified\":\"2026-11-02T07:00:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-5.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/\",\"name\":\"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-5.png\",\"datePublished\":\"2026-11-02T06:57:26+00:00\",\"dateModified\":\"2026-11-02T07:00:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-5.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-cover-5.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/","og_locale":"el_GR","og_type":"article","og_title":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA","og_description":"The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in PTEN-deficient metastatic hormone-responsive prostate cancer. Withdrawal is a strategic decision, not simply a failure. Why companies withdraw An applicant may withdraw at any stage before the Committee adopts its opinion. [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/","og_site_name":"PQRA","article_published_time":"2026-11-02T06:57:26+00:00","article_modified_time":"2026-11-02T07:00:30+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"1 \u03bb\u03b5\u03c0\u03c4\u03cc"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026","datePublished":"2026-11-02T06:57:26+00:00","dateModified":"2026-11-02T07:00:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-5.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/","url":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/","name":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026 - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-5.png","datePublished":"2026-11-02T06:57:26+00:00","dateModified":"2026-11-02T07:00:30+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-5.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-cover-5.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/withdrawn-extension-applications-reading-ibrance-and-truqap-in-october-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1235"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1235\/revisions"}],"predecessor-version":[{"id":1260,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1235\/revisions\/1260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1259"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}